223 related articles for article (PubMed ID: 24752271)
1. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
[TBL] [Abstract][Full Text] [Related]
2. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
3. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
4. Novel Protease Inhibitors Containing C-5-Modified
Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
[TBL] [Abstract][Full Text] [Related]
5. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
[TBL] [Abstract][Full Text] [Related]
6. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
[TBL] [Abstract][Full Text] [Related]
7. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
[TBL] [Abstract][Full Text] [Related]
8. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
[TBL] [Abstract][Full Text] [Related]
9. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
10. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
[TBL] [Abstract][Full Text] [Related]
11. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
Ide K; Aoki M; Amano M; Koh Y; Yedidi RS; Das D; Leschenko S; Chapsal B; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2011 Apr; 55(4):1717-27. PubMed ID: 21282450
[TBL] [Abstract][Full Text] [Related]
12. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.
Amano M; Miguel Salcedo-Gómez P; Yedidi RS; Delino NS; Nakata H; Venkateswara Rao K; Ghosh AK; Mitsuya H
Sci Rep; 2017 Sep; 7(1):12235. PubMed ID: 28947797
[TBL] [Abstract][Full Text] [Related]
13. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
[TBL] [Abstract][Full Text] [Related]
14. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
15. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
[TBL] [Abstract][Full Text] [Related]
16. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
[TBL] [Abstract][Full Text] [Related]
17. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.
Hattori SI; Hayashi H; Bulut H; Rao KV; Nyalapatla PR; Hasegawa K; Aoki M; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962341
[TBL] [Abstract][Full Text] [Related]
18. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
Wang Y; Liu Z; Brunzelle JS; Kovari IA; Dewdney TG; Reiter SJ; Kovari LC
Biochem Biophys Res Commun; 2011 Sep; 412(4):737-42. PubMed ID: 21871444
[TBL] [Abstract][Full Text] [Related]
19. A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Parham GL; Nyalapatla PR; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2015 May; 59(5):2625-35. PubMed ID: 25691652
[TBL] [Abstract][Full Text] [Related]
20. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
